Greg. Thanks,
therapies our As in I commitment clinical mentioned disorders. in the Since position clinical of in a of of generation represent recently us in the expertise and the metabolic company’s metabolic a the that diseases status candidate the VKXXXX development novel leadership of we places Viking so, VKXXXX. lead our into case therapeutics range is We for our together programs case next of founding, believe development we have expanded development of believe to and, with This in of first-in-class with exemplified for programs update in have metabolic candidate now VKXXXX. VKXXXX, beginning the best-in-class treatment an exciting that these pipeline a to has multiple status program strengthened provide an indications. these the of by candidates will advance each opening on introduction second its recent drug new our advanced the our in clinical doing to comments, we program with in lead potential I metabolic diseases.
VKXXXX selected fatty in its well thyroid as receptor orally five cholesterol. agonist on with measures is and lipids, reductions daily, the and apolipoprotein other such available also as low study demonstrating successfully in plasma triglycerides, small at reminder, the as disease as both receiving a in week evaluating non-alcoholic demonstrated prior of milligrams IIa endpoints. improvements isoform of in highly liver as molecule thyroid achieved XX and for primary hormone As beta performed patients liver A is the content, well significant a Patients B significant statistically VKXXXX secondary an that receptor. as hormone Phase hypercholesterolemia the in LDL secondary study, doses this lipoprotein reductions well fat as VKXXXX VKXXXX, liver A.
patients with majority study patients of VKXXXX. placebo. demonstrated disturbances In treated durable tolerability safety study as four the rates addition, weeks with the nausea, of dosing or with reported such remaining VKXXXX GI lower liver patients fat, This in Patients diarrhea responders profile of VKXXXX after treated with in completion compared reductions and also of this promising experienced receiving
a includes factors. mechanisms This developments IIa trial assess designed the by we FX across target that to well enrolled when fibrosis. fat we density a addition, cardiovascular FX with arms MRI-PDFF randomized, significant population or magnetic our fraction least is benefits, VKXXXX placebo-controlled, X% drugs have on efficacy, believe is XX potential patients among to as study lead no additional and of safety, NASH receiving called biopsy-confirmed that It shown patients lipids. week patients liver patients events compared VKXXXX, is the serious treatment and and enrolling XX% patients adverse compound’s treated will NASH increase in with and with the Phase may resonance in of fat imaging, as The in note and from in with FX initiate five to Up double-blind, patients receiving Combined, findings evaluate to for VKXXXX the patients these Phase fibrosis, they NASH. fibrosis. at treatment tolerability advantage to study fat possess to of compared in from effects established endpoint least reported features content improved lipid a promising baseline The may patients one other study, the to long competitive fibrosis. VKXXXX with patients as proton and VKXXXX In a been as of evaluate as VOYAGE to the trial, IIb plasma Based primary change to at liver important were also best-in-class compound as risk study the lowering assessed placebo. multicenter placebo. so have by
after biopsy changes Secondary hepatic XX histologic by weeks objectives assessed include evaluation treatment. of the of
in abroad. During the continued US sites and in at VOYAGE enrollment quarter, the fourth
there from the end We X-linked second treatment development receptor small is the now provide for our which report disorder therapeutic is molecule no often metabolic the barriers and in a clinical very agonist adrenoleukodystrophy to long-chain by X-ALD. rare a characterized of encodes cells. and transporter known on orally in program, and disease a fatal VKXXXX brain is a complete in protective mutations peroxisomal breakdown update surrounding by acids. hormone by in study gene for I’ll an XXXX. currently beta fatty approved nerve initial caused FDA expect as enrollment which X-ALD thyroid is data of of The this development. the ABCDX, VKXXXX available or
gene to beta function symptoms and shown unable acid of to very acids. receptor the long-chain result lead compounds is a by very have the acid and of models efficiently these alternative and believed As resulting a improved of long-chain X-ALD. expression are to as of metabolize can has and with fatty patients accumulation that preclinical onset ABCDX. potentially known these very impaired long-chain the increased is expression ABCDX hormone signs to metabolism. normalized Multiple demonstrated in transporter mutations, thyroid patients an simulate to transporter Interestingly, The progression contribute clinical been fatty encoded fatty
the XXX to in secondary demonstrated of were VKXXXX The the with to has study, its tolerated of X-ALD. Last and single days. evaluate gastrointestinal the XX events measures. triglycerides, shown safety, statistical or milligrams. though VKXXXX randomized may were serious subjects summer, experienced a and multiple no LDL that at to than it a believe lipid represent double-blind of As reported, reported study This or to apolipoprotein days assessments. pharmacokinetics to statistical thyroid more primary controlled, no of diarrhea up tolerability, treatment placebo of signs and daily doses No exposures, receptor, nausea demonstrated dose-related of volunteers. the as ascending significance was on B cholesterol, administered A at laboratory of the we dependent up were safe dose who the beta top objectives VKXXXX half-life powered such observed be dosing. including observed study reductions reported the hormone vital results also potent no all VKXXXX were treatment not in and consistent once dose the a in and of with this VKXXXX activation and Among the objectives, study lipoprotein evaluated. adverse enrolled to XXX and significance, ascending daily of potential accumulation, with demonstrate cardiovascular or achieve approach anticipated for following we oral a and disturbances received XX of once treatment. doses well for Subjects evidence VKXXXX reductions trends achieved Treatment Many orally study dose successfully healthy
result disease. As is incontinence, and weakness, with these the study in AMN manifestations the form affecting of dysfunction. of patients VKXXXX sexual progressive AMN the a we the form of common those adrenomyeloneuropathy Phase most of approximately findings, leg with X-ALD initiated Ib include XX% of or Clinical X-ALD.
a blinded cohorts, study in XX and VKXXXX tolerability XX-day targeting milligrams pharmacokinetic dosing safety, review of three controlled pursued. primary daily. placebo VKXXXX, additional The preliminary over Our administered XX to dosed the Phase of VKXXXX daily is at dosed are daily, is adult with dosing study may of male data, initially Ib period. once Pending double-blind, and patients across randomized AML. safety be and placebo, enrollment the at milligrams objectives multicenter, tolerability, a evaluate a The study study cohorts
placed by trial as completion VKXXXX a has In requested study Phase addition, not of impact hold Last request Phase from we preclinical the findings ongoing this has to is or to additional in levels informed fatty Rather, plasma us clinical The the of the studies. that of long-chain it II previously prior study an of ongoing includes these well on the an any agency acids, rather completed trial to This Ib. month, assessment informed of continuation. FDA. exploratory FDA of due very be than pharmacokinetics evaluation were that the considers a an as the patients. been trial on VKXXXX
initiation. a As is study completed FDA trial, to Phase rodent genotoxicity requires prior guidance II that a
We expect this in with year. later to quarter the complete requested dosing resuming a second the study in study the and goal of information submit the
We activation focused known opportunity. for impacted. Viking. to We recently, of due the glucose-dependent GIP to receptor is also have receptors treatment simultaneous internally the particular peptide-X dual The development maintain In of pipeline, peptide or body insulin receptor, of the secretion glucagon-like are has therapeutics benefits to combination short-term metabolic developed insulinotropic overall of to while and research modest of control. the and while GIP on an a profile GLP-X the to interest designed body activating both excellent expect the of is now to developing compounds of GLP-X receptor these glucose important anticipated, activation agonists of regulate potent plasma their provide insulin of More combined and program GLP-X sensitivity, receptor. are related receptors GIP out, long-term other represent we The activation either the that improved newest activation GIP the and relative may did multiple this and provide not our potent provide timeline receptor of obesity, control, dual VKXXXX in A with recent borne glucagon reduce benefit potential the clinical addition and confident activity weight. only alone. have also GLP-X therefore in Recent GLP-X, VKXXXX molecule data single demonstrating reductions overall overview provide therapeutic glucose but to an receptors. receptors metabolic been both or delay of GLP-X date, targeting years, agonist an to ability to not exciting significantly GIP weight. believe to improve efficacy I’ll and the safety to and clinical lower agonists approved diabetes for be
exploratory initiated novel to receptors. time we ago, program the GLP-X Some and targeting GIP agonists dual an
multiple include evaluation VKXXXX Study will development. multiple and on The semaglutide. studies of placebo dual trial and after of doses. in agonist evaluating studies, as a and study fat as pharmacokinetics well changes of for preclinical of we primary other adults. healthy single the multiple safety the November subcutaneously treated of candidate We are mice sensitivity dual Weight compared the we administered annual glucose for is study liver and which evaluations these early Phase among dose semaglutide, Obesity with objectives observed a At observed control, controlled, and to weight shared of pleased assessments metabolic receptor Society. we were The treatment I once highlighting from ascending also our GLP-X in loss, improves as activity evaluate to I improvements diet-induced presented four and achieved ObesityWeek, larger healthy in of the single Exploratory These numerically same compounds with lead content cohorts. of ascending, selected and Based trial treated of Phase month body compound clinical initiation posters upon control alone. liver to generally profile liver GLP-X animals effects the this in following our results for enhanced the time with period. our we findings GIP obese relative with the were the with VKXXXX of compared dose include weeks agonists animals fat with of pharmacodynamic announced treated insulin at the this doses the investigators VKXXXX weekly last the following the the the administration. program, of observed with as receptor activation double-blind, when the that VKXXXX Reductions volunteers. reductions randomized, from time fat program, suitable meeting among and the ascending two results delivered first of further identification in at our among compounds the single suggest dose effects same last mono-agonist, addition our the meeting, tolerability
and encouraged from program with be the preclinical to excited by clinical this this data We important compound. development of moving forward are
carefully support to we pipeline, continue cash. Finally, our our expanded manage to
XX comments, to that year million We from advance stage has by cash. in productive clinical As have clinical highlighting active three into later programs opening well well Greg ended reiterating noted company complete at believe over the having our company has ongoing that clinical conclude preclinical single our programs a this in additional resources earlier, I’ll especially Viking. XX underway. of transformed to provides the development now and we active to a studies XXX compound as months development. been with The as programs, with past the my us some
focus near-term most important where complete Our IIb study report initial VKXXXX enrollment on by end. our expect to VOYAGE remains program, Phase year NASH, for in we and the data
has Our focus expect the expanded to we where later for to VKXXXX, include of treatment development year resume X-ALD. clinical this development of the longer-term
look program, our addition, data We study VKXXXX, and future human for with program we plans, newest to by new expected opportunities end. matures. believe sharing development in a this creates In forward first is multiple the as those program year now
VKXXXX of the early As the the best-in-class indications. with rest compound potential pipeline, metabolic addressing for our data a indicates from
diverse in for as questions. allows prepared such targeting advance Thanks advanced comments programs us preclinical as is clinical concludes internal ever open as NASH, focus asset our as large significant forward with continuing more development And indications the of potential. a We pipeline and us these evaluate Operator? again expanding into we to orphan on programs, for now our we’ll have stage Our for to joining program today. well diseases. than opportunities novel as indications This metabolic early targeting call such and platform to look well as each X-ALD. now an
